Rappta Therapeutics is a late pre-clinical stage biopharmaceutical company that is revolutionizing the field of cancer treatment. They have developed a groundbreaking series of anti-cancer molecular glues that reactivate a key tumor suppressor known as protein phosphatase 2A (PP2A). The team at Rappta Therapeutics has an in-depth understanding of PP2A biology and has used their expertise to create proprietary compounds that effectively reactivate PP2A.

By acting as a glue, their compounds enable the three subunits of PP2A to bind together, restoring its tumor-suppressive function and targeting a wide array of oncogenic substrates. This innovative approach to cancer treatment has significant potential, not only in the field of oncology but also for treating other human diseases. By restoring PP2A activity and cellular homeostasis, Rappta Therapeutics offers a unique and promising therapeutic strategy.

Located in Helsinki, Finland, Rappta Therapeutics is at the forefront of biopharmaceutical innovation, striving to provide effective treatments for patients worldwide